Inquiry Basket
DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate, as a potent EGFR inhibitor and it overcomes resistant to EGFR.
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-00009 | 10 mg | $298 | Inquiry |
DM1-SMCC, a potent cytotoxic agent, plays a vital role in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. Here are four key applications of DM1-SMCC:
Cancer Treatment: At the forefront of targeted cancer therapy, DM1-SMCC is a cornerstone in ADCs engineered to specifically seek out cancer cells. By binding to antibodies that recognize tumor-associated antigens, this cytotoxic agent is delivered directly to malignant cells, minimizing harm to healthy tissues. This precision targeting not only enhances treatment effectiveness but also reduces systemic side effects, heralding a paradigm shift in cancer care.
Pharmacokinetics Studies: In the realm of pharmacokinetics research, DM1-SMCC is a crucial tool for unraveling the behavior and distribution of ADCs in both preclinical and clinical settings. Understanding the journey of these conjugates in the body—from absorption to elimination—is paramount for optimizing dosing strategies and improving therapeutic results. These studies are instrumental in predicting clinical responses and potential adverse reactions.
Drug Development: Serving as a prototypical payload, DM1-SMCC plays a pivotal role in designing the next generation of ADCs. By manipulating linker chemistry or pairing with diverse monoclonal antibodies, scientists can craft innovative ADCs with enhanced stability, potency, and selectivity. This adaptability is key to tailoring treatments for a spectrum of cancer types.
Mechanism of Action Studies: Delving into the intricate mechanisms of ADCs’ cytotoxic effects on cancer cells, DM1-SMCC empowers researchers to explore cellular uptake, intracellular trafficking, and release within targeted cells. These investigations offer profound insights into how ADCs induce cell death, shedding light on resistance mechanisms and optimizing therapeutic approaches. This deep understanding is pivotal for refining cancer treatment strategies and overcoming therapeutic challenges.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
